Key Highlights
- Eli Lilly stock began trading Friday at $1,208.37, marking a 14.4% gain year to date and outpacing the S&P 500’s performance
- GLP-1 medications Mounjaro and Zepbound generated approximately 65% of first-quarter 2026 revenue
- The pharmaceutical giant introduced Foundayo, an oral GLP-1 treatment, with projections showing GLP-1 products will exceed 65% of Q2 revenue
- First-quarter earnings per share reached $8.55, surpassing analyst projections of $6.97, while revenue hit $19.80 billion — representing a 55.5% year-over-year increase
- The company deployed over $20 billion toward acquisitions and strategic collaborations in 2026 to expand beyond its GLP-1 portfolio
Eli Lilly (LLY) stock commenced Friday’s session at $1,208.37, hovering close to its 52-week peak of $1,238.00. The pharmaceutical behemoth has delivered a 14.4% return year to date, outperforming both the pharmaceutical sector’s 11.6% advance and the broader S&P 500 index.
The Indianapolis-based drugmaker posted first-quarter 2026 earnings of $8.55 per share, handily exceeding Wall Street’s $6.97 consensus forecast. Total revenue reached $19.80 billion, crushing analyst expectations of $17.82 billion and representing a 55.5% jump compared to the prior-year quarter.
The company’s GLP-1 franchise — led by Mounjaro and Zepbound — fueled the majority of this expansion. These two medications alone accounted for roughly 65% of first-quarter revenues. Following the domestic rollout of Foundayo, Lilly’s newly approved oral GLP-1 therapy for obesity management, analysts anticipate GLP-1 products will comprise more than 65% of second-quarter sales.
Foundayo’s introduction positions Lilly in renewed head-to-head competition with Novo Nordisk (NVO), which debuted its oral Wegovy formulation in January 2026, securing a temporary first-mover advantage.
Strategic Expansion Beyond Weight Loss Drugs
While GLP-1 medications continue delivering robust growth, Lilly has aggressively pursued portfolio diversification to mitigate concentration risk in the obesity and diabetes markets.
The company’s emerging non-GLP-1 pipeline includes Omvoh for inflammatory bowel conditions, Jaypirca addressing specific hematologic malignancies, Ebglyss approved for atopic dermatitis treatment, Kisunla targeting early-stage Alzheimer’s disease, and Inluriyo launched for metastatic breast cancer patients.
Jaypirca has demonstrated particularly impressive momentum. The Food and Drug Administration expanded its indication in late 2025 to include patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The European Medicines Agency’s Committee for Medicinal Products for Human Use has subsequently recommended broader approval encompassing all treatment lines for CLL therapy, with the European Commission’s final determination expected shortly.
Lilly anticipates a comparable FDA label expansion decision for Jaypirca before year-end. Approval would substantially enlarge the addressable patient population across U.S. markets.
Regarding mergers and acquisitions, Lilly allocated more than $20 billion throughout 2026 toward strategic transactions spanning oncology, neuroscience, cardiovascular therapeutics, gene editing technologies, and vaccine development. This capital deployment signals management’s commitment to sustainable long-term diversification.
Stock Valuation and Wall Street Perspective
At current trading levels, LLY shares command a forward price-to-earnings multiple of 30.67 — elevated relative to the pharmaceutical industry’s 18.76 average but trading below the stock’s own five-year historical mean of 34.56. The company’s market capitalization currently stands at $1.14 trillion.
Full-year 2026 earnings per share projections have climbed over the past two months, rising from $33.86 to $35.67. Looking ahead to 2027, analyst estimates have similarly increased from $42.56 to $44.61.
Institutional investors control 82.53% of outstanding shares. World Investment Advisors expanded its position by 12.1% during the first quarter of 2026, purchasing an additional 2,936 shares to reach a total holding of 27,134 shares.
Wall Street sentiment remains predominantly bullish. Goldman Sachs maintains a buy recommendation with a $1,283 price objective. Jefferies recently elevated its target to $1,350, also rating the stock a buy. Morgan Stanley reaffirmed its overweight stance in June.
Among 30 analysts monitored by MarketBeat, 23 assign buy ratings, with the consensus price target settling at $1,235.07.
The notable exception: HSBC downgraded shares to reduce in March, establishing an $850 price target.
Management’s fiscal 2026 guidance projects earnings per share between $35.50 and $37.00, while the sell-side consensus currently stands at $35.74.
